48 results about "Neutrophile" patented technology

The features of the present invention for providing a novel neutrophil activator are as follows. 1. An IL-8 production accelerator containing at least one selected from GlcCer[d18:2(4E,8Z) / 18:0], GlcCer[d18:2(4E,8Z) / 20:0], GlcCer[d18:2(4E,8Z) / 22:0], GlcCer[d18:2(4E,8Z) / 24:0], and GlcCer[d18:2(4E,8Z) / 26:0] as an active ingredient. 2. An IL-8 production accelerator containing GlcCer[d18:2(4E,8E) / 24:0] as an active ingredient. 3. An IL-8 production accelerator containing at least one selected from GlcCer[t18:1(8Z) / 24:0] and GlcCer[t18:1(8Z) / 26:0] as an active ingredient. 4. An IL-8 production accelerator containing GlcCer[d18:1(4E) / 20:0] as an active ingredient. 5. An IL-8 production accelerator containing at least one selected from Cer(t18:0 / 22:0), Cer(t18:0 / 23:0), Cer(t18:0 / 24:0), Cer(t18:0 / 25:0), and Cer(t18:0 / 26:0) as an active ingredient. 6. An IL-8 production accelerator containing at least one selected from Cer[t18:1(8Z) / 24:0] and Cer[d18:2(4E,8Z) / 20:0] as an active ingredient. 7. An IL-8 production accelerator containing at least one selected from Oryza Ceramide A, Oryza Ceramide B, and Oryza Ceramide C as an active ingredient.

Described herein are methods and compositions relating to methods of inhibiting neutrophils, e.g., inhibiting NET release or NETosis, by means of a DEspR inhibitor, e.g., an anti-DEspR antibody reagent. In some embodiments, the methods can relate to the treatment of a disease, e.g., cancer or a disease wherein neutrophils; NETs; or NETosing or NETting neutrophils contribute to pathogenesis, chronicity, or worsening of disease. In some embodiments, the DEspR inhibitor can be a bi-specific reagent or an antibody-drug conjugate.

A family of bioactive compounds identified in self-resolving inflammatory exudates is disclosed. The compounds give UV chromophores characteristic of a conjugated triene double bond system coupled to an auxochrome allylic to the triene. Further elucidation of the compounds reveals that they have a resolvin backbone conjugated to a peptide or amino acid moiety via an auxochrome. In some embodiments the auxochrome is sulfur. However, the auxochrome may be NH, CH2 or O. The compounds have potent bioactivity, in vitro, and, in vivo, including promoting resolution of infection, stimulating macrophage phagocytosis of bacteria; protecting tissues from neutrophil mediated damage, promoting tissue repair and regeneration and preventing or limiting second organ reflow / reperfusion damage.

The present application relates to the field of biological medicine, in particular to a sensitizing agent for constructing a neutrophilic asthma animal model, a construction method and application. The present application uses Haemophilus influenzae outer membrane vesicles and ovalbumin as a sensitizing agent to construct a neutrophilic asthma animal model, and the test results show that the level of neutrophils in the blood and lung lavage fluid of mice is significantly increased compared with the treatment of ovalbumin as a sensitizing agent alone. The constructed mouse neutrophilic asthma model can be used for the research on the mechanism of clinical neutrophilic asthma and the development of neutrophilic asthma drugs.

The application belongs to the technical field of medicine, and specifically discloses a kind of nasal spray composition and nasal spray and application, the nasal spray composition includes the following components: hyaluronic acid, trehalose, N-acetyl-L-cysteine, methylene succinic acid, gallic acid, taurine, coenzyme Q10, rosemary essential oil.The nasal spray composition provided by the application is accurately adjusted, can give full play to the advantages of each component, provide better nasal ventilation and humidity.The nasal spray composition provided by the application can inhibit the excessive activation of LPS-induced neutrophil Netosis in vitro culture and the excessive activation of LPS-induced mouse airway neutrophil Netosis, thereby reducing the inflammatory response in the nasal cavity.

The application provides a culture method and composition for prolonging the in-vitro survival time of neutrophils. The composition provided by the application comprises prednisolone and beta-mercaptoethanol, which can prolong the survival time of neutrophils. The method provided by the application has low cost, simple operation, small interference to cell function, can guarantee an experimental window of 3-4 days, and has good application value.

The invention relates to the technical field of biological medicine preparations, in particular to application of targeted nanoparticles in treatment of osteoporosis. The targeted nano-particles CL-NPs (at) NEs are developed, CL can stimulate lipolysis of bone marrow adipocytes, osteogenic differentiation is promoted, and therefore the bone marrow microenvironment is improved; meanwhile, autologous neutrophil is used as a carrier to transport CL-NPs, bone marrow fat cells beta3AR are accurately targeted, and the osteoporosis microenvironment can be further improved. Experiments prove that CL-NPs (at) NEs stimulate a bone marrow fat cell beta3 adrenoceptor in a targeted manner, can effectively improve OP, has safety and has the potential to become a novel medicine for osteoporosis.

This invention discloses an antimicrobial peptide, its pharmaceutical composition, and its applications. The invention optimizes the structure of the antimicrobial peptide through deuteration modification technology, significantly enhancing its targeted binding ability to β-1,3-D-glucan synthase. The affinity of this antimicrobial peptide for the aforementioned target is 9-27 times that of the control peptide. In vitro assays show that its minimum inhibitory concentration (MIC) against nine standard Candida strains is consistently 0.002 μg / mL, exhibiting significantly superior activity compared to fluconazole, anidoxurine, and the control peptide. It also exhibits extremely low cytotoxicity against L02 human normal hepatocytes. In in vivo experiments, in a neutropenic mouse model of Candida albicans infection, the antimicrobial peptide at all doses showed superior reduction in renal fungal load compared to anidoxurine and the control peptide. The antimicrobial peptide of this invention combines highly efficient anti-Candida activity, low cytotoxicity, and excellent in vivo efficacy, providing a safe and effective candidate drug for the treatment of drug-resistant candidiasis and possessing good clinical translational value.

The invention provides methods of determining the neutrophil level in a sample by determining the level of CD16b, including the intracellular form of CD16b in a sample, such as a blood sample. The methods may further comprise the determination of lactate levels Also provided are associated diagnostic and therapeutic methods. Further provided are kits and devices for performing the methods, particularly lateral flow kits and devices.

This invention discloses an engineered attenuated Salmonella VNP-SNase, its preparation method, and its applications, including methods and compositions for treating various solid tumors or metastatic tumors. Specifically, engineered attenuated Salmonella capable of expressing and secreting SNase is recruited to the tumor microenvironment through tumor targeting, specifically degrading intratumoral neutrophil extracellular traps (NETs), weakening the killing effect of NETs on Salmonella, increasing its intratumoral colonization, and simultaneously improving the tumor-promoting and immunosuppressive effects caused by NETs, ​​while effectively preventing bacteria from off-target into normal organs. By releasing SNase to activate / regulate the immune system and directly / indirectly inhibit tumors, it can act as an effective immune effector.

The invention discloses application of a polygonatum odoratum polysaccharide extract in preparation of a medicine for treating viral pneumonia, and belongs to the technical field of medicines. Through experiments, the applicant discovers that the polygonatum odoratum polysaccharide extract can significantly reduce the fluorescence intensity of neutrophils and macrophages in poly (I: C) induced zebrafish viral pneumonia model swimming sacs, has an obvious antiviral effect on zebrafish, can reduce the expression of pro-inflammatory factors tnf alpha, il6 and il12, has an obvious anti-inflammatory effect, and can be used for preparing anti-inflammatory drugs for treating zebrafish viral pneumonia. The compound is expected to be used for preparing anti-viral pneumonia drugs.

The invention provides a neutrophil transporter, a marker CD66b of the neutrophil transporter, and application of combination of the CD66b and other indexes to early diagnosis or auxiliary diagnosis of blood coagulation disorder. The invention provides CD66b, application of CD66b and other index combinations to preparation of reagents or kits for early diagnosis or auxiliary diagnosis of blood coagulation disorders, related reagents and kits, and a system for early diagnosis or auxiliary diagnosis of blood coagulation disorders. The CD66b, the combination of the CD66b and other indexes, the reagent or the kit and the system provided by the invention have the effect of early diagnosis or auxiliary diagnosis of the blood coagulation disorder.

The invention discloses bifidobacterium adolescentis BAS05 and application thereof in preparation of a medicine for preventing or treating intestinal inflammation, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium adolescentis BAS05 disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No. 22515. The bifidobacterium adolescentis BAS05 can inhibit DSS from inducing neutrophil to gather towards the intestinal tract of the zebra fish, so that a theoretical reference and a guidance basis are provided for developing a medicine for preventing or treating intestinal inflammation by utilizing the bifidobacterium adolescentis BAS05.

The invention discloses a hyperlipidemia risk prediction model and a risk prediction system during treatment of TSC by SRL, and belongs to the field of disease model prediction. According to the hyperlipemia risk prediction model disclosed by the invention, three parameters including SRL (Sirolimus) blood drug valley concentration, baseline triglyceride and neutrophil count of an object to be evaluated are input; the output is the risk probability of the to-be-evaluated object suffering from hyperlipemia; large sample data is adopted to train a model, cases suffering from hyperlipemia are positive samples, other cases are negative samples, and the model is selected from XGBoost, a support vector machine, a random forest, a decision tree and LightGBM. The key risk factors of hyperlipemia after SRL treatment are disclosed, accurate prediction of the risk of SRL-related hyperlipemia is achieved, especially the RO-AUC of the XGBoost model reaches 0.95, and the method can be applied to detection instruments, monitoring networks, wearable devices and other scenes.

The invention discloses a method for inducing HL-60 cells to generate a neutrophil extracellular trap net and application of the method. The method comprises the following steps: firstly, inducing and differentiating HL-60 cells into neutrophile granulocyte-like cells by using dimethyl sulfoxide (DMSO), and then stimulating the differentiated cells by using phorbol ester (PMA), thereby inducing to form the neutrophile granulocyte extracellular trapping net. Preferably, the final concentration of the DMSO is 0.8%-1.5%, the final concentration of the PMA is 50-400 nM, and the stimulation time is 2-4 hours. According to the invention, a polylysine-coated substrate is adopted to enhance the structural stability of NETs, and SYTOX Green nucleic acid dye is adopted for fluorescence detection. According to the invention, a complete and standardized experimental system formed from the HL-60 cell to the NETs is successfully established, the technical problems of unstable primary cell source and poor experimental repeatability are overcome, the operation is simple and convenient, the result is reliable, and an ideal tool is provided for related research of the NETs.

The invention provides an irinotecan hydrochloride lipidosome composition. The irinotecan hydrochloride lipidosome composition is prepared from the following components in a specific weight ratio: irinotecan hydrochloride, hydrogenated soybean phospholipid, cholesterol and mPEG2000-DSPE. The invention also provides a preparation method of the liposome composition. The liposome disclosed by the invention can be used for remarkably reducing the serious hematotoxicity of irinotecan hydrochloride, and particularly remarkably reducing the occurrence rate of neutropenia.

The present disclosure discloses a data acquisition and analysis method based on diabetes data analysis and processing equipment, and relates to the field of diabetes data analysis and prediction. The equipment includes a computer, a placement rack and a flow cytometer. The mitochondrial membrane potential data in the neutrophil is performed independent evaluation and analysis. If the proportion of cells with increased mitochondrial membrane potential are in the neutrophil is greater than 70%, the person is at the risk of diabetes, otherwise the risk is lower, so that the subsequent development of diabetes in a person with normal blood glucose can be predicted, and the diabetes can be prevented in advance.

This invention relates to the field of bioengineering technology, specifically to a method for preparing neutrophil gelatinase-associated lipid transport protein and its antibody. Specifically, using pET23a(+) as the expression vector, the NGAL gene with six His tags fused to its N-terminus under promoter control is introduced into *E. coli* for induced expression. After purification using a Ni Focurose 6FF column and a molecular sieve column, tag-free NGAL protein with a purity ≥95% is obtained. Subsequently, the NGAL protein is used to repeatedly immunize Japanese rabbits, and serum is collected after each immunization. Qualified serum is screened using a two-dimensional agar diffusion assay, and then purified using the aforementioned antigen to prepare an antigen affinity purification column, yielding a highly active NGAL polyclonal antibody. The high-purity recombinant NGAL of this invention not only possesses activity but is also low-cost, not limited by raw materials, and can be mass-produced, possessing potential and wide-ranging application value in clinical and in vitro diagnostics.

The present application relates to the field of biological medicine technology, and relates to a kind of oral squamous cell carcinoma related marker and drug screening method. By 5R 16S rRNA-seq analysis and representative fluorescence in situ hybridization technique verification, the abundance of Capnocytophaga leadbetteri (C. leadbetteri) in oral squamous cell carcinoma (Oral Squamous Cell Carcinoma, OSCC) tissue is significantly higher than that in normal tissue, and it can be used as the diagnostic marker of OSCC. The present application further clarifies the specific molecular mechanism of the bacteria promoting tumor progression, excludes environmental microbial interference through aseptic mouse model, and directly proves that C. leadbetteri single bacterial colonization can induce oral epithelial hyperplasia and barrier damage. Experiments confirm that the bacteria up-regulate chemotactic factors by activating TLR4 / MyD88 / NF-κB signaling axis, recruit neutrophils to form pro-tumor immune microenvironment. In vivo animal model confirms that after using BAY 11-7082 to inhibit NF-κB or using anti-Ly6G antibody to eliminate neutrophils, the tumor volume and weight are significantly reduced (P<0.01), and the present application provides a new treatment target and drug screening theoretical basis for OSCC.

The present invention relates to a pharmaceutical composition comprising a protein complex, and its pharmaceutical applications for treating or preventing conditions characterized by impaired leukocyte production, such as neutropenia. The protein complex can also be formed by linking an immunoglobulin Fc region to a bioactive polypeptide via a non-peptide polymer linked to the immunoglobulin Fc region. [Solution] The present invention provides a method for treating chemotherapy-induced neutropenia in patients who require it by administering an effective amount of efrapegrastim to the patient, and a method for treating radiation-induced neutropenia in patients who require it by administering an effective amount of efrapegrastim to the patient.

The invention discloses application of lactobacillus salivarius LS08 in preparation of a medicine for preventing or treating intestinal inflammation, and belongs to the technical field of microorganisms. The preservation number of the lactobacillus salivarius LS08 disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No.22988. The lactobacillus salivarius LS08 can inhibit the DSS from inducing neutrophil to gather towards the intestinal tract of the zebra fish, so that a theoretical reference and a guidance basis are provided for developing the medicine for preventing or treating the intestinal inflammation by utilizing the lactobacillus salivarius LS08.

The invention provides an extraction method of a tumor cell culture supernatant and an induction method for promoting formation of a neutrophil extracellular trap net, and belongs to the technical field of cell induction. The extraction method of the tumor cell culture supernatant can efficiently extract and obtain the tumor cell culture supernatant containing inflammation-inducing factors, can be used for observing whether the tumor cell culture supernatant can induce formation of neutrophil extracellular trapping nets NETs or not, and further enriches phenotype detection of tumor cell induced inflammatory response. The invention further provides an induction method for promoting formation of the neutrophil extracellular trapping net. The induction method has high sensitivity. By adopting the scheme, the tumor cell culture supernatant can be used as an inducer to quickly induce the formation of a neutrophil extracellular trapping net, so that the activity of neutrophil and the reactivity of the supernatant inducer are greatly ensured, and the formation of a self non-specific extracellular trapping net is reduced.

The invention discloses a directional immunoregulation composition based on medicinal and edible substances and a preparation method thereof in the fields of functional foods, medical nutrition and massive health. The composition is prepared from the following raw materials in parts by weight through synergistic effects: 20-35 parts of astragalus membranaceus, 70-110 parts of Chinese yam, 2-8 parts of lucid ganoderma, 8-18 parts of fructus lycii and 8-18 parts of rhizoma polygonati. Through the synergistic effect of various medicinal and edible substances, immune indexes such as leukocytes and neutrophils can be directionally regulated and controlled, the myelosuppression symptom is effectively improved, meanwhile, the level of inflammatory factors such as serum IL-6 and CRP is reduced, the good anti-inflammatory regulation effect is achieved, the medicinal and edible substances are adopted as the raw materials, synergistic compatibility is scientific and reasonable, and the health-care food is suitable for being popularized and applied. The traditional Chinese medicine composition is suitable for long-term use.

The present invention aims to develop a technique for measuring neutrophil counts using small amounts of blood, such as 1 μL or less, as obtained by fingertip puncture. [Solution] A method for measuring the number of neutrophils in a blood sample is provided, which includes measuring superoxide anions in the presence of bortezomib or ixazomib or a salt thereof.

The application discloses a metal-organic framework metal antibiotic and a preparation method and application thereof, the metal antibiotic comprising manganese-containing nanoparticles; a PCN MOF material formed on an outer layer of the manganese-containing nanoparticles; and a hybrid membrane formed on an outer layer of the PCN MOF material, the hybrid membrane being composed of macrophages and neutrophils. The metal-organic framework metal antibiotic can activate a cGAS-STING pathway signal channel, achieve the purpose of treating diseases related to the cGAS-STING pathway, and inhibit inflammation caused by activation of the cGAS-STING pathway, especially against implant-related biofilm infection, can avoid excessive inflammation after infection clearance, promote tissue repair, and thus provide a new possibility for a new metal immunotherapy platform.

The invention discloses an egg white protein source peptide with an effect of improving immunocompromise and application of the egg white protein source peptide, and belongs to the technical field of small molecule peptides. Protease is used for carrying out enzymolysis on egg white protein, an enzymolysis product with the molecular weight smaller than 1000 Da is cut out to prepare albumin peptide, and the albumin peptide contains tetrapeptide MSPF with the effect of improving the immunocompromise. Animal model function verification shows that the tetrapeptide MSPF and the albumin peptide containing the peptide fragment can significantly improve low immune function, the number of macrophages is increased by 62.94%, the number of neutrophils is increased by 62.69%, and the content of interferon gamma is increased by 76.11%, so that the immunity of the organism is enhanced. The food-borne bioactive peptide is high in biological safety. Therefore, the tetrapeptide MSPF or the albumin peptide containing the peptide fragment can be applied to the preparation of medicines for improving immunocompromise or health-care foods for enhancing immunity, and has good market prospects and application potential.

The invention discloses a nano-drug system for targeted therapy of colorectal cancer with fusobacterium nucleatum infiltration and a preparation method of the nano-drug system. The invention belongs to the technical field of biology, and particularly relates to a nano-drug system for targeted therapy of colorectal cancer with fusobacterium nucleatum infiltration and a preparation method of the nano-drug system. An active ingredient of the medicine with the tumor cell activity inhibiting effect or the anti-tumor activity contains NM-coated PLGA-MTI-OXA, the NM-coated PLGA-MTI-OXA is composed of neutrophile granulocyte membrane vesicles and PLAG-MTI-OXA, the PLAG-MTI-OXA is nanoparticles obtained by loading chemotherapeutic drugs MTI and OXA on polylactic acid-glycolic acid copolymer, and the neutrophile granulocyte membrane vesicles are derived from bone marrow neutrophile granulocytes. The NM-coated PLGA-MTI-OXA developed by the invention can effectively target colorectal tissues infiltrated by fusobacterium nucleatum, successfully realizes antibacterial and anti-tumor effects, and has application value.

The present invention relates to a novel cerium oxide nanocomposite and a composition for preventing or treating kidney diseases, comprising same as an active ingredient. The present invention can be used as an excellent therapeutic composition with maximized biostability and in vivo inflammation control efficiency, achieved by modifying the surface of cerium oxide nanoparticles with an optimal content of a pyrrolidone derivative polymer. The cerium oxide nanocomposite of the present invention can be used as an excellent therapeutic composition that significantly improves the survival rate of patients with acute kidney injury, which is an intractable severe disease, by reducing reactive oxygen species and neutrophils in kidney tissue and repairing tubular damage.

The present application relates to the technical field of pharmaceutical chemistry, in particular to a preparation method and application of a berberine and isovitexin nanomedicine. The application is used in the preparation of a drug for treating diseases related to inflammation mediated by neutrophils. The berberine and isovitexin or the structural analogues of berberine and isovitexin form nanoparticles in a carrier-free form through self-assembly. The berberine and isovitexin nanomedicine has a synergistic anti-inflammatory and antioxidant effect, can efficiently inhibit key inflammatory mediators, realize high-efficiency anti-inflammatory and antioxidant synergy, and significantly improve the effect of preventing and treating acute inflammation.

The invention belongs to the technical field of drug delivery, and particularly relates to HLNP (at) NEs and a preparation method and application thereof. The preparation method comprises the following steps: preparing lipid nanoparticles DOTAP-DOPE-LNP, modifying the lipid nanoparticles with hyaluronic acid (HA), and finally combining the modified DOTAP-DOPE-HA-LNP with neutrophils (NEs) to jointly form a nucleic acid drug targeting delivery system HLNP-NEs, so that the system can improve the targeting property of the drug and improve the biocompatibility of a carrier; the active targeting property on the bone marrow tumor can be well realized.